Protecting Lean Mass on GLP-1 Therapy: The Four Levers That Work

GLP-1 muscle loss can occur because medical weight loss may involve losing some lean mass along with fat. In a 72-week tirzepatide substudy, about 25% of the weight lost was lean mass, while 75% was fat mass. The placebo group showed roughly the same 75/25 split, placing the finding within the broader pattern of weight loss. Lean mass also includes more than skeletal muscle. The practical levers are protein intake, resistance training, energy deficit, and risk-based monitoring.^1,2

What the GLP-1 Muscle Loss Data Show

The available tirzepatide data show greater fat loss than lean-mass loss. In the SURMOUNT-1 body-composition substudy, body weight decreased by 21.3%, fat mass by 33.9%, and lean mass by 10.9% over 72 weeks. The placebo group lost 5.3% of body weight, 8.2% of fat mass, and 2.6% of lean mass.¹

Approximately 75% of the weight lost came from fat mass, while 25% came from lean mass. The placebo group had approximately the same proportions.¹ That comparison matters because it suggests the lean-mass change occurred within the usual physiology of losing weight. The study does not show that tirzepatide selectively removed muscle.

The substudy included 160 people, and 73% were female.¹ You should not treat its 75/25 split as a result established specifically in men. It gives you a useful reference point, but your baseline body composition and repeat measurements provide the individual context.

The parent SURMOUNT-1 trial studied tirzepatide in adults with obesity or overweight.³ These data do not establish the body-composition effects of semaglutide or compare the two medications.

Lean Mass, Muscle, and What the Scans Measure

Lean mass is a broad measurement category. It does not represent skeletal muscle alone, so a decline in lean mass cannot be read automatically as lost muscle tissue or reduced physical ability.²

Dual-energy X-ray absorptiometry (DXA) estimates fat mass, lean mass, and bone mineral using low-dose X-rays. The SURMOUNT-1 substudy used DXA to measure body-composition changes.¹

Bioelectrical impedance analysis (BIA) estimates fat-free mass by measuring resistance to a small electrical current. BIA can support repeat clinical monitoring when advanced imaging is not available, but its fat-free-mass estimate is not interchangeable with skeletal muscle.²

Neither measurement tells your physician everything about strength, movement, or muscle quality. A review of GLP-1-based obesity treatment found that lean-tissue loss does not necessarily indicate impaired strength or physical performance.²

Scale weight alone provides even less information. A fat-free mass index calculator relates fat-free mass to your height, which can help you follow a body-composition trend alongside weight. Use the same measurement method over time when possible. One reading is a data point. Repeat readings show the direction of change.

A result within a standard range does not show whether you are moving toward your own body-composition goal. Weight, lean mass, strength, and labs create the pattern your physician can use.

Muscle Reserve After Age 40

Age-related changes can reduce the lean-mass reserve available before medical weight loss begins.² If your baseline is lower, further lean-tissue loss may leave less room before strength or function starts to suffer.

The tirzepatide substudy did not establish a separate result for men over 40. Your age should prompt closer baseline assessment and follow-up. It should not be used to assume that you will lose a specific amount of muscle.

Four Levers for GLP-1 Muscle Loss

Four practical levers can support lean-mass preservation during weight loss. Each one needs to fit your food intake, training history, rate of weight change, symptoms, and baseline measurements.

Build the plan from your measurements, then reassess it as weight, lean mass, strength, and labs change.

Adequate Protein Intake

Adequate protein intake gives resistance training the nutritional support required to maintain lean tissue. The 2026 clinical review supports food-first nutrition counseling, with protein supplements or nutritionally complete meal replacements considered when regular food intake is insufficient.²

Reduced appetite or gastrointestinal symptoms can make adequate intake difficult. Your physician should assess what you are eating before assuming that a supplement solves the problem. A protein intake calculator can give you an individualized starting number without applying one gram target to everyone.

Structured Resistance Training

Structured resistance exercise provides the direct training stimulus for maintaining strength and lean tissue. The clinical review includes resistance exercise as part of the supportive-care model for people using GLP-1-based obesity treatment.²

A separate meta-analysis of resistance training during energy deficits found that lean-mass gains were impaired compared with training without an energy deficit. The effect size was −0.57, with a p value of 0.02. Strength gains remained comparable between groups, with an effect size of −0.31 and a p value of 0.28.⁴

That meta-analysis did not study people taking GLP-1 medications. It does show that resistance training may improve strength even when an energy deficit limits lean-mass gains. Your training plan should come from your current ability, injury history, and access to equipment. The study does not provide a universal set-and-repetition plan.

A Manageable Energy Deficit

The size and duration of an energy deficit can affect your ability to build or preserve lean mass. In the resistance-training meta-regression, a deficit of about 500 kilocalories per day prevented gains in lean mass.⁴

The authors advised people training to preserve lean mass during weight loss to avoid deficits greater than 500 kilocalories per day.⁴ This threshold came from resistance-training studies rather than GLP-1 trials. It is not a daily calorie prescription.

Your physician can interpret the pace of weight loss alongside appetite, food intake, training performance, and body-composition trends. Faster scale movement may look productive while making adequate nutrition and training harder to maintain.

Hormonal Status and Risk-Based Monitoring

Risk-based monitoring should include more than total body weight. The clinical review recommends assessing muscle quantity, muscle quality, physical function, bone health, and nutritional adequacy.²

A physician may also measure testosterone as part of your broader hormonal status. The sources reviewed here do not establish testosterone replacement therapy as a method for preserving muscle during GLP-1 treatment. A testosterone result belongs within the full clinical pattern, including symptoms and other laboratory findings.

For men over 40, the broader pattern can include testosterone, cortisol, sleep, and nutrition alongside body composition. A panel of 55+ biomarkers gives your physician a wider view of hormonal status, inflammation, and cardiovascular risk.

Useful follow-up may include:

• Repeat body-composition measurements using a consistent method
• Strength or functional measures that reflect what your body can do
• Review of food intake and gastrointestinal symptoms
• Laboratory assessment based on your nutritional and hormonal risks

Opt Health’s body-composition program combines laboratory data, physician review, nutrition, training context, and repeat measurement. The purpose of monitoring is to adjust the plan when your numbers or physical function move in the wrong direction.

Supplements With Evidence Behind Them

Supplements remain secondary to adequate food intake, resistance exercise, and clinical monitoring. The 2026 review describes creatine, essential amino acids or leucine, and beta-hydroxy-beta-methylbutyrate as adjunctive options supported mainly by indirect or phenotype-specific evidence.²

The same evidence limit applies to fiber, probiotics, omega-3 fatty acids, and multi-ingredient products.² The review does not establish that these products prevent muscle loss during GLP-1 treatment. If your food intake is insufficient, protein supplementation or a nutritionally complete meal replacement has more direct support within the review’s care model.²

Separate Evidence for Semaglutide and Tirzepatide

The 75/25 body-composition result comes from the tirzepatide substudy, where the same split occurred in the placebo group. It does not establish the same percentage for semaglutide, and the cited sources do not compare the medications on muscle loss.

Questions about semaglutide and tirzepatide require evidence designed for that comparison. You can also review GLP-1 treatment for men for the wider clinical factors that may affect your treatment plan.

The Opt Take on GLP-1 Muscle Loss

Body composition and hormonal status should be measured rather than assumed. At Opt Health, a physician reads those results together with your symptoms, food intake, training context, sleep, and rate of weight change. The physician builds a plan around your baseline, then adjusts it as your numbers move.

Membership begins with a blood panel of 55+ biomarkers taken at home or at a local partner lab. The panel spans hormones, inflammation, cardiovascular risk, and more. A 1:1 physician consultation connects the lab results with your body-composition trend and physical function. Scale weight remains one part of the pattern.

A full blood panel and physician consultation repeat every three to four months. Consistent body-composition measurements can be reviewed alongside weight, lean mass, strength, and hormonal status. The follow-up shows whether the plan fits the direction of your results. Fixed protein targets and training templates cannot account for the same individual pattern. Your plan stays tied to your measurements and goals.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.